Epizyme, Inc.

Nuvalent appoints Grant Bogle to its Board of Directors, enhancing its transition from development to commercialization of novel kinase inhibitors, with pivotal data expected in 2025.

The global epigenetics drugs & diagnostic technologies market is projected to grow from USD 17.39 billion in 2024 to USD 56.54 billion by 2033, driven by diagnostics (94.9% share in 2023), oncology (70.0% share in 2023), and North America's dominance (41.5% share in 2023). Key growth factors include technological advancements, rising prevalence of chronic diseases, and increasing R&D activities.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

Ipsen employee Dishant Gupta charged with insider trading after allegedly profiting from stock transactions based on non-public knowledge of the company's $247 million buyout of Epizyme. Gupta, who agreed to plead guilty, faces a monetary penalty and is barred from serving as an executive or director of any publicly traded company. Ipsen's oncology portfolio expansion includes acquisitions like Epizyme's Tazverik and Merrimack Pharmaceuticals' Onivyde, along with deals for cancer drug development programs.

I-DXd (ifinatamab deruxtecan) showed clinically meaningful responses in pretreated extensive-stage SCLC patients, with a confirmed response rate of 26.1% at 8 mg/kg and 54.8% at 12 mg/kg. The 12 mg/kg dose was selected as optimal for further study.